Oncology

EC Grants Celltrion Avastin Biosimilar Marketing Authorization

August 20th 2022

By Skylar Jeremias

The European Commission (EC) authorized Celltrion Healthcare’s bevacizumab biosimilar referencing Avastin for marketing across the European Union, making it the seventh bevacizumab biosimilar to be approved in the region.

Not So Different: Biosimilars Oncology Roundup for July 2022—Podcast Edition

August 7th 2022

By Skylar Jeremias

Podcast

On this episode of Not So Different, we recap some of the biggest biosimilars news that happened over the past month, including updates on clinical trials for oncology biosimilars as well as a survey on whether patients were given adequate information prior to switching a biosimilar.

Biosimilars Oncology Roundup: July 2022

August 1st 2022

By Skylar Jeremias

Article

Trials for denosumab biosimilars are ramping up and researchers are concerned whether patients with cancer switching to biosimilars have been adequately informed beforehand.

Deal Would Have Teva Pay $4.25 Billion to Settle US Opioid Lawsuits

July 27th 2022

By The Center for Biosimilars

Article

The deal follows a string of trials and settlements totaling $550 million in separate cases around the country.

Companies Clinch Deals for Global Biosimilar Commercialization

July 26th 2022

By Skylar Jeremias

Article

Prestige Biopharma and Intas Pharmaceuticals join forces to partner on a bevacizumab biosimilar for multiple countries, and Hikma Pharmaceuticals makes a deal with Celltrion Healthcare for the commercialization of an adalimumab biosimilar.

A Biosimilar Adoption Program Saved a US Nonprofit Health System $29.6M in 2 Years

July 23rd 2022

By Deana Ferreri, PhD

Article

The first 2 years of the program created $26.9 million in cost savings and “biosimilar adoption rates that greatly exceed the US national average."

Alvotech to Launch Pharmacokinetics Study for Denosumab Biosimilar

July 20th 2022

By Mary Caffrey

Article

The biosimilar candidate would reference Prolia, used in the treatment of osteoporosis in postmenopausal women and to treat bone loss in adult men and women who are at increased risk of fracture. It is also planned as a biosimilar for Xgeva, which is indicated to prevent skeletal fractures in patients with cancer.

Posters Assess Quality of Trastuzumab, Denosumab Biosimilars in Cancer

July 19th 2022

By Skylar Jeremias

Article

Posters from the American Society of Clinical Oncology’s annual meeting showed the safety and efficacy of a trastuzumab biosimilar and a denosumab biosimilar in different types of cancer.

Rituximab Biosimilars Prove Effective in Large B-Cell Lymphoma

July 14th 2022

By Skylar Jeremias

Article

Abstracts from the European Hematology Association Congress 2022 confirmed comparable safety and effectiveness profiles between 2 rituximab biosimilars and the reference product (Rituxan) in patients with large B-cell lymphoma.

Report: Biosimilar Uptake Accelerates in US—and So Do the Savings

July 13th 2022

By Mary Caffrey

Article

Amgen's early view said health care savings from the use of these biologic therapies climbed to $3 billion in the second quarter of 2022, for total of $18 billion over the past 6 years.